ROR1 and sarcoma: Additionally, anti-ROR1-CAR-T and anti-nti-IGF1R-CAR-T cells have demonstrated anti-tumor activity against sarcomas in vitro and have effectively suppressed sarcoma surge in both localized and scattered pre-established xenotransplantation models (Huang et al., 2015[48]).